top of page



Cold Chain Logistics: Safeguarding Comparator Integrity in Clinical Trials
Cold-chain logistics play a pivotal role in pharmaceutical supply, ensuring patient safety and trial continuity. This is especially true in the oncology sector, where most therapies are temperature-sensitive and in high demand, amplifying the need for robust cold-chain infrastructure. Cold-chain logistics refers to the temperature-controlled transport and storage of pharmaceutical products. For biologics, cell and gene therapies and many oncology medications, maintaining a na

Clinical Services International (CSI)
Mar 31


Navigating Trump-Era Tariffs
CSI’s Strategic Approach to Mitigating Clinical Trial Supply Disruption Recent developments in U.S. trade policy are shaking up supply chains, not just within the United States but worldwide. With the re-introduction of Trump-era tariffs on key goods, companies engaged in clinical research must rethink their sourcing and logistics strategies. Clinical Services International (CSI) is proactively addressing these challenges to support our clients amid this uncertain climate. Wh

Clinical Services International (CSI)
Apr 25, 2025


Advancements in Oncology
This month, we are focusing on Oncology and have reflected on the notable advancements to oncology medications in recent years....

Clinical Services International (CSI)
Feb 1, 2024


Case Study: Global Biotech Oncology Partnership
How CSI supplied large quantities of ruxolitinib to a biotech’s ongoing Phase 3 oncology study involving 14 countries, nine depots and 67 site shipments Challenge CSI was approached by a biotech conducting a full global Phase 3 oncology study spanning 14 countries. We were asked to purchase and supply a significant quantity of ruxolitinib within a tight timeframe: with the contract signed in December 2022, the client aimed to have the first sites supplied by March 2023. The

Clinical Services International (CSI)
Jul 11, 2023


Blockbuster Oncology Products in Clinical Trial Supplies
Oncology products monopolise the list of best-selling drugs. With a huge range of indications that is only growing, therapies become more specific to tumour or cell pathologies and increasing patient numbers. Several oncology products now have ‘blockbuster’ status where sales exceed $1 billion annually. This is relevant for clinical trials as more regulators require evidence of efficacy in comparison to the standard of care, which is likely to be one of the blockbuster produc

Vanessa Dekou
Nov 21, 2020
News and Insights
.png)
bottom of page